Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095096 | 0.94 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL5086925 | 0.94 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL5088808 | 0.94 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL5086807 | 0.94 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL2016293 | 0.94 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL13309593 | 0.94 | LTA4H (0.42) | PLA2G2ANR5A1TSHRLTA4HNPC1 | |
| SCHEMBL16440321 | 0.90 | PLA2G2A (0.44) | PLA2G2ANR5A1TSHRLTA4HCNR1 | |
| SCHEMBL17407555 | 0.84 | PLA2G2A (0.51) | PLA2G2ANR5A1TSHRLTA4HCNR1 | |
| SCHEMBL5488935 | 0.82 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 | |
| SCHEMBL2712563 | 0.82 | PLA2G2A (0.54) | PLA2G2ANR5A1TSHRCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-9611279-B2 | Zinc complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-04-04 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002268-A1 | ZINC COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002268-A1 | ZINC COMPLEX | SLC39A11, SLC39A3, SOD1 | PLA2G2A 3775/4885NR5A1 1379/4885TSHR 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.